150 Strafford Avenue, #303
42 articles with Intact Vascular
Journal of Endovascular Therapy Publishes Peer Reviewed Article Underscoring the Clinical Impact of Post-Angioplasty Dissections
Intact Vascular’s Tack Endovascular System® is highlighted as a treatment option for post-PTA dissections
Intact Vascular Announces $25 Million Financing with Vensana Capital to Drive Commercialization of the Tack Endovascular System®
Intact Vascular, Inc. announced a $25 million financing with Vensana Capital as the lead investor.
Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons Conference
Presentations Highlight the Tack Endovascular System® for Focal Dissection Repair Device Following Balloon Angioplasty
Intact Vascular, Inc. announced the first commercial use of its Tack Endovascular System in multiple sites across the United States.
First-of-its-Kind Treatment for Post-Angioplasty Above-the-Knee Dissections Now Available
Presentations Showcase the Importance of Treating Post-Angioplasty Dissections
Intact Vascular Announces Launch of the Tack Endovascular System® in the EU and First Commercial Use in Germany
The Tack® implant is a first-of-its kind device for patients with peripheral arterial disease and/or critical limb ischemia
First-of-its-kind study designed to demonstrate safety and efficacy of the Tack Endovascular System® in treating post-PTA dissections below the knee
Reporting to the CEO, Mr. MacKinnon will oversee the creation of a U.S. based sales team and will play a central role in planning and executing the company’s projected launch of the Tack Endovascular System® in 2019.
Data to be presented as a Late-Breaking Clinical Trial at the 2018 VIVA Conference
Intact Vascular, Inc. announced the schedule of key presentations that will be featured during a symposium sponsored together with Philips at the 19th Annual NCVH Conference in New Orleans on May 31.
Intact Vascular Announces Enrollment Completion of the Tack Optimized Balloon Angioplasty III (TOBA III) Clinical Trial
Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has completed enrollment.
Intact Vascular Announces $20 Million Series C Financing to Fund Company through PMA Approval of the Tack Endovascular System®
Financing designed to fund the Company through Pre-Market Approval of the Tack Endovascular System for the treatment of post-angioplasty dissections above the knee.
Intact Vascular Welcomes TOBA BTK Trial One-Year Clinical Study Results Publication in Catheterization and Cardiovascular Intervention
Multi-center pilot study focused on collecting data supporting the safety and performance of the Tack Endovascular System® in subjects with Critical Limb Ischemia (CLI) due to vascular disease below the knee.
TOBA II BTK Trial Enrollment Ahead of Schedule for the Tack Endovascular System in Below the Knee Disease
Intact Vascular announced the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial surpassed the 100 patient milestone, advancing enrollment well ahead of schedule.
Intact Vascular: Positive Twenty-Four Month Tack Optimized Balloon Angioplasty ("TOBA") Single Center Results Presented at VEITHsymposium Conference
The TOBA study enrolled 138 subjects at 13 sites in Europe.
Intact Vascular Announces Enrollment Of First European Patient In Tack Optimized Balloon Angioplasty II Below The Knee (TOBA II BTK) Clinical Trial With The Tack Endovascular System
Intact Vascular Release: FDA Approves 6-Month Primary Endpoint For The Tack Endovascular System In Below The Knee Disease
Intact Vascular Adds Howard Rosen To Its Executive Management Team As VP Marketing And Business Development
Intact Vascular Announces Completion Of Enrollment In The Tack Optimized Balloon Angioplasty II (TOBA II) Clinical Trial